Elpiscience has a robust pipeline of globally innovative cancer immunotherapies, covering a wide range of oncology targets. Through internal R&D expertise and partnerships with global biopharmaceutical companies, Elpiscience endeavors to advance at least one innovative program into the clinic each year.
Elpiscience has established comprehensive R&D capabilities including proprietary monoclonal and bispecific antibody discovery, translational research, clinical development, CMC and GMP manufacturing. Our integrated R&D engine enables us to advance our innovative programs rapidly and cost-effectively.
Elpiscience fosters an inclusive work environment comprised of diverse, committed, and highly accomplished professionals. Together, we live Elpiscience’s values as we advance scientific innovation and develop transformative medicines that improve cancer patients’ lives.